Cendakimab
Names
[ CAS No. ]:
2151032-62-9
[ Name ]:
Cendakimab
Biological Activity
[Description]:
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis)[1].
[Related Catalog]:
[Target]
IL-13
[In Vitro]
Cendakimab (RPC4046; ABT 308; CC-93538) fully neutralizes IL-13-induced thymus and activation-regulated chemokine from lung epithelial A-549 cells with potencies ranging from 80 to 513 pM[1].
[References]
Chemical & Physical Properties
No Any Chemical & Physical Properties